Bone marrow serves as the life-long home for hemato-poietic stem cells(HSCs)and is the most radio-sensitive organ^([1]).Acute ionizing radiation exceeding 1 Gray(Gy)causes severe damage in bone marrow while no effecti...Bone marrow serves as the life-long home for hemato-poietic stem cells(HSCs)and is the most radio-sensitive organ^([1]).Acute ionizing radiation exceeding 1 Gray(Gy)causes severe damage in bone marrow while no effective drug has been approved in clinical.In a recent work pub-lished in MedComm,Gao and her team reported,for the first time,cannabidiol(CBD)as an outstanding radioprotection agent targeting acute radiation-induced hematopoietic injury^([2]).Within two weeks post radiation,CBD can pro-mote the stemness of hematopoietic stem cells to a regular level.Using single-cell RNA sequencing(scRNA-seq)and functional assay,the authors decoded molecular changes underlying radiation-induced damage and CBD-induced recovery in HSCs.展开更多
Background:Cannabidiol(CBD)has numerous therapeutic properties,and is used to treat neurological conditions,such as neuroinflammation.However,the optimal dose of CBD to penetrate the brain requires further investigati...Background:Cannabidiol(CBD)has numerous therapeutic properties,and is used to treat neurological conditions,such as neuroinflammation.However,the optimal dose of CBD to penetrate the brain requires further investigation.The primary aim of this study was to use a mouse model and the intrabuccal route for CBD administration to determine the optimal dose at which CBD can penetrate the brain.The secondary aim was to determine whether sex is a confounding factor.Methods:Thirty adult Kramnik mice,divided equally into three groups,were ad-ministered CBD oil intrabuccally at three doses-10,20,and 30 mg/kg,euthanized 6 h later,and whole brain,urine,and blood samples were collected.Liquid chro-matography with tandem mass spectrometry was used to analyze the collected samples.Results:CBD and its three metabolites—7-carboxy cannabidiol(7-COOH-CBD),7-hydroxy cannabidiol(7-OH-CBD)and 6-hydroxy cannabidiol(6-OH-CBD),were identified and quantified in all samples.The 10 and 20 mg/kg doses of CBD produced similar results in the brain,but the group given the 10 mg/kg dose had the least vari-ation.The 30 mg/kg dose yielded the highest abundance of CBD and its metabolites in all samples,but also the greatest variation.Sex only became a confounding factor at 30 mg/kg.Conclusions:This study shows that the intrabuccal route of CBD administration is reliable and the 10 mg/kg dose of CBD is recommended in mice because there were good CBD metabolite concentrations in all samples,with the least variation among the doses,and sex was not a confounder at 10 mg/kg.展开更多
Background:Chronic Gulf War Illness(GWI)is characterized by cognitive and mood impairments,as well as persistent neuroinflammation and oxidative stress.This study aimed to investigate the efficacy of Epidiolex®,a...Background:Chronic Gulf War Illness(GWI)is characterized by cognitive and mood impairments,as well as persistent neuroinflammation and oxidative stress.This study aimed to investigate the efficacy of Epidiolex®,a Food and Drug Administration(FDA)-approved cannabidiol(CBD),in improving brain function in a rat model of chronic GWI.Methods:Six months after exposure to low doses of GWI-related chemicals[pyridostigmine bromide,N,N-diethyl-meta-toluamide(DEET),and permethrin(PER)]along with moderate stress,rats with chronic GWI were administered either vehicle(VEH)or CBD(20 mg/kg,oral)for 16 weeks.Neurobehavioral tests were conducted on 11 weeks after treatment initiation to evaluate the performance of rats in tasks related to associative recognition memory,object location memory,pattern separation,and sucrose preference.The effect of CBD on hyperalgesia was also examined.The brain tissues were processed for immunohistochemical and molecular studies following behavioral tests.Results:GWI rats treated with VEH exhibited impairments in all cognitive tasks and anhedonia,whereas CBD-treated GWI rats showed improvements in all cognitive tasks and no anhedonia.Additionally,CBD treatment alleviated hyperalgesia in GWI rats.Analysis of hippocampal tissues from VEH-treated rats revealed astrocyte hypertrophy and increased percentages of activated microglia presenting NOD-,LRR-and pyrin domain-containing protein 3(NLRP3)complexes as well as elevated levels of proteins involved in NLRP3 inflammasome activation and Janus kinase/signal transducers and activators of the transcription(JAK/STAT)signaling.Furthermore,there were increased concentrations of proinflammatory and oxidative stress markers along with decreased neurogenesis.In contrast,the hippocampus from CBD-treated GWI rats displayed reduced levels of proteins mediating the activation of NLRP3 inflammasomes and JAK/STAT signaling,normalized concentrations of proinflammatory cytokines and oxidative stress markers,and improved neurogenesis.Notably,CBD treatment did not alter the concentration of endogenous cannabinoid anandamide in the hippocampus.Conclusions:The use of an FDA-approved CBD(Epidiolex®)has been shown to effectively alleviate cognitive and mood impairments as well as hyperalgesia associated with chronic GWI.Importantly,the improvements observed in rats with chronic GWI in this study were attributed to the ability of CBD to significantly suppress signaling pathways that perpetuate chronic neuroinflammation.展开更多
Cannabidiol(CBD)is the active constituent of Cannabis sativa and exhibits a diverse range of pharmacologic effects,including anticancer,antibacterial,anti-inflammatory,antioxidant,and antiepileptic properties.The phar...Cannabidiol(CBD)is the active constituent of Cannabis sativa and exhibits a diverse range of pharmacologic effects,including anticancer,antibacterial,anti-inflammatory,antioxidant,and antiepileptic properties.The pharmacologic effects of CBD and its molecular mechanisms are reviewed with the objective of proposing novel approaches for basic research and clinical applications of CBD and related pharmaceuticals.展开更多
Background: Myocardial ischemia in addition to other several cardiac syndromes represent a pathological proinflammatory state alongside a complex cellular microenvironment that can be modified by using cannabinoids. C...Background: Myocardial ischemia in addition to other several cardiac syndromes represent a pathological proinflammatory state alongside a complex cellular microenvironment that can be modified by using cannabinoids. Cannabidiol (CBD), a non-psychoactive compound of cannabis has been recently proposed as an immudomodulatory and cardioprotective drug. Objectives: In this systematic review we sought to clarify and summarize the clinical and preclinical evidence of potential benefit of the use of CBD in coronary syndromes. Methods: We conducted a systematic search and review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Review of Animal Data from Experimental Studies (CAMARADES) guidelines, in the electronic database from PubMed, Web of Science and Scopus up to April 2022 using predefined search terms. Pre-specified exclusion and inclusion criteria were considered, finally 11 articles were chosen to be included for this peer review. Results: Currently there are no good-quality clinical trials with the use of CBD in acute or chronic coronary syndromes. A total of 11 preclinical studies where prescreened and 5 demonstrated reproducible positive cardiovascular outcomes on in-vivo models treated with CBD. Mechanisms of CBD cardioprotection observed: 1) reduction in oxidative stress and inflammation, 2) activation of adenosine receptors and 3) increased expression of angiotensin type 2-receptor. Experimental models included ischemia/reperfusion injury, myocardial infarction, arrhythmias, and metabolic syndrome-like conditions. Conclusion: No clinical recommendation can be issued with the current evidence, on the use of CBD in acute and chronic coronary syndromes. Based on preclinical evidence, we considered there is enough evidence to propose the development of well-designed clinical trials that include CBD in the management of coronary syndromes.展开更多
Colorectal tumors often create an immunosuppressive microenvironment that prevents them from responding to immunotherapy.Cannabidiol(CBD)is a non-psychoactive natural active ingredient from the cannabis plant that has...Colorectal tumors often create an immunosuppressive microenvironment that prevents them from responding to immunotherapy.Cannabidiol(CBD)is a non-psychoactive natural active ingredient from the cannabis plant that has various pharmacological effects,including neuroprotective,antiemetic,anti-inflammatory,and antineoplastic activities.This study aimed to elucidate the specific anticancer mechanism of CBD by single-cell RNA sequencing(scRNA-seq)and single-cell ATAC sequencing(scATAC-seq)technologies.Here,we report that CBD inhibits colorectal cancer progression by modulating the suppressive tumor microenvironment(TME).Our single-cell transcriptome and ATAC sequencing results showed that CBD suppressed M2-like macrophages and promoted M1-like macrophages in tumors both in strength and quantity.Furthermore,CBD significantly enhanced the interaction between M1-like macrophages and tumor cells and restored the intrinsic anti-tumor properties of macrophages,thereby preventing tumor progression.Mechanistically,CBD altered the metabolic pattern of macrophages and related anti-tumor signaling pathways.We found that CBD inhibited the alternative activation of macrophages and shifted the metabolic process from oxidative phosphorylation and fatty acid oxidation to glycolysis by inhibiting the phosphatidylinositol 3-kinase-protein kinase B signaling pathway and related downstream target genes.Furthermore,CBD-mediated macrophage plasticity enhanced the response to anti-programmed cell death protein-1(PD-1)immunotherapy in xenografted mice.Taken together,we provide new insights into the anti-tumor effects of CBD.展开更多
Cannabinoids, the active components of Cannabis sativa Linnaeus, have received renewed interest in recent years due to their diverse pharmacologic activities such as cell growth inhibition, anti-inflammatory effects a...Cannabinoids, the active components of Cannabis sativa Linnaeus, have received renewed interest in recent years due to their diverse pharmacologic activities such as cell growth inhibition, anti-inflammatory effects and tumor regression, but their use in chemotherapy is limited by their psychotropic activity. To date, cannabinoids have been successfully used in the treatment of nausea and vomiting, two common side effects that accompany chemotherapy in cancer patients. Most non-THC plant cannabinoids e.g. cannabidiol and cannabigerol, seem to be devoid of psychotropic properties. However, the precise pathways through which these molecules produce an antitumor effect have not yet been fully characterized. We therefore investigated the antitumor and anti-inflammatory activities of cannabidiol (CBD) in human prostate cancer cell lines LNCaP, DU145, PC3, and assessed whether there is any advantage in using cannabis extracts enriched in cannabidiol and low in THC. Results obtained in a panel of prostate cancer cell lines clearly indicate that cannabidiol is a potent inhibitor of cancer cell growth, with significantly lower potency in non-cancer cells. The mRNA expression level of cannabinoid receptors CB1 and CB2, vascular endothelial growth factor (VEGF), PSA (prostate specific antigen) are significantly higher in human prostate cell lines. Treatment with Cannabis extract containing high CBD down regulates CB1, CB2, VEGF, PSA, pro-inflammatory cytokines/chemokine IL-6/IL-8. Our overall findings support the concept that cannabidiol, which lacks psychotropic activity, may possess anti-inflammatory property and down regulates both cannabinoid receptors, PSA, VEGF, IL-6 and IL-8. High CBD cannabis extracts are cytotoxic to androgen responsive LNCaP cells and may effectively inhibit spheroid formation in cancer stem cells. This activity may contribute to its anticancer and chemosensitizing effect against prostate cancer. Cannabidiol and other non-habit forming cannabinoids could be used as novel therapeutic agents for the treatment of prostate cancer.展开更多
Cannabidiol(CBD),a nonpsychotropic phytocannabinoid that was once largely disregarded,is currently the subject of significant medicinal study.CBD is found in Cannabis sativa,and has a myriad of neuropharmacological im...Cannabidiol(CBD),a nonpsychotropic phytocannabinoid that was once largely disregarded,is currently the subject of significant medicinal study.CBD is found in Cannabis sativa,and has a myriad of neuropharmacological impacts on the central nervous system,including the capacity to reduce neuroinflammation,protein misfolding and oxidative stress.On the other hand,it is well established that CBD generates its biological effects without exerting a large amount of intrinsic activity upon cannabinoid receptors.Because of this,CBD does not produce undesirable psychotropic effects that are typical of marijuana derivatives.Nonetheless,CBD displays the exceptional potential to become a supplementary medicine in various neurological diseases.Curently,many clinical trials are being conducted to investigate this possibility.This review focuses on the therapeutic effects of CBD in managing neurological disorders like Alzheimer's disease,Parkinson's disease and epilepsy.Overall,this review aims to build a stronger understanding of CBD and provide guidance for future fundamental scientific and clinical investigations,opening a new therapeutic window for neuroprotection.展开更多
Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or oral...Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was observed, which limits its clinical use. In the present study, we have studied in mice the anti-inflammatory and anti-nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan-induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD. We therefore propose that Cannabis clone 202 (Avidekel) extract is superior over CBD for the treatment of inflammatory conditions.展开更多
Δ9-tetrahydrocannabinol(THC)of cannabis is the main psychoactive component which is a global significant concern to human health.Evaluation on THC reported its drastic effect on the brain dopaminergic(DAergic)system ...Δ9-tetrahydrocannabinol(THC)of cannabis is the main psychoactive component which is a global significant concern to human health.Evaluation on THC reported its drastic effect on the brain dopaminergic(DAergic)system stimulating mesolimbic DA containing neurons thereby increasing the level of striatal DA.Cannabidiol(CBD),with its anxiolytic and anti-psychotic property,is potent to ameliorate the THC-induced DAergic variations.Legal authorization of cannabis use and its analogs in most countries led to a drastic dispute in the elicitation of cannabis products.With a recent increase in cannabis-induced disorder rates,the present review highlighted the detrimental effects of THC and the effects of CBD on THC induced alterations in DA synthesis and release.Alongside the reported data,uses of cannabis as a therapeutic medium in a number of health complications are also being briefly reviewed.These evaluated reports led to an anticipation of additional research contradictory to the findings of THC and CBD activity in the brain DAergic system and their medical implementations as therapeutics.展开更多
Background and purpose: Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has been shown by us, to have an anti-inflammatory effect in collagen-induced arthritis in DBA mice and in type 1 diabetes in...Background and purpose: Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has been shown by us, to have an anti-inflammatory effect in collagen-induced arthritis in DBA mice and in type 1 diabetes in NOD mice. As inflammation is a process involved in diabetes type 2, we administered CBD to Psammomys obesus (sand rats), a species which develops diabetes type 2 when fed high-energy (HE) diet, to investigate whether we can hinder the development of the disease. Experimental Approach: Male Psammomys obesus were kept on a high energy diet during the experiments. They were treated with CBD (i.p injection, 5 mg/kg, 5 times/week) for 4 weeks and kept (without CBD) for another 29 - 39 days. The weights of the animals as well as blood glucose and plasma insulin levels were determined and the morphology of the pancreatic islets was examined. Key results: CBD significantly reduced blood glucose levels in Psammomys obesus, without effecting body weight. Plasma insulin levels were significantly higher in the CBD-treated group. The most striking effect noted was the marked decrease of the destruction of pancreatic islets and beta cells. Conclusions and implications: CBD partially protects pancreatic islets and beta cells from destruction. CBD lowers significantly the blood glucose level and increases insulin level in Psammomys obesus with diabetes type 2, but does not lead to obesity. As CBD already has been administered to patients for other medical indications we propose its use as a therapeutic agent in diabetes type 2.展开更多
Cannabidiol (CBD), one of the most studied phytocannabinoids, is non-psychotropic and can induce protective effects on the central nervous system against acute and chronic brain injury. Interestingly, CBD inhibits pro...Cannabidiol (CBD), one of the most studied phytocannabinoids, is non-psychotropic and can induce protective effects on the central nervous system against acute and chronic brain injury. Interestingly, CBD inhibits processes relating to amyloid beta (Aβ)-induced neurotoxicity in mouse models of Alzheimer’s disease, though the detailed molecular mechanism underlying the CBD neurotoxicity modulation is not fully understood. In this study, using atomic force microscopy, we find that CBD promotes the aggregation of Aβ peptides, enhancing the formation of Aβ oligomers, also known as Aβ-derived diffusible ligands (ADDLs). The CBD-mediated sequestration of Aβ monomers in soluble ADDLs could reduce neurotoxicity. This study highlights a possible role of CBD in modulating the formation of ADDL aggregates and provides insight into potentially neuroprotective properties of CBD in Alzheimer’s disease.展开更多
Objective:To study the protective effect of cannabidiol(CBD)on rats with pulmonary fibrosis and explore the possible mechanism of the use of CBD in the treatment of pulmonary fibrosis.Methods:Sixty SD rats were random...Objective:To study the protective effect of cannabidiol(CBD)on rats with pulmonary fibrosis and explore the possible mechanism of the use of CBD in the treatment of pulmonary fibrosis.Methods:Sixty SD rats were randomly divided into the normal control group,model group,prednisone group,CBD low,medium and high dose groups(12,36,108 mg/kg,ig),10 rats in each group.Except for the normal control group,the other 5 groups were all induced by tracheal injection of bleomycin to rat models of pulmonary fibrosis.After modeling,the rats were given intragastric administration once a day for 28 consecutive days and samples were taken.The degree of pulmonary edema was detected;the pathological changes of lung tissue were observed by HE and Masson staining;tumor necrosis factorα(TNF-α),interleukin-1β(IL-1β),interleukin-6(IL-6)and lung tissue superoxide dismutase(SOD),malondialdehyde(MDA),hydroxyproline(HYP)contents were measured by ELISA,transforming growth factor-β1(TGF-β1)andα-smooth muscle protein(α-SMA)concentration were detected by immunocytochemical method,real-time fluorescent quantitative PCR(qRT-PCR)method was used to detect the mRNA expression levels of TGF-β1,α-SMA,Nrf2 and nuclear transcription factor-κB p65(NF-κB p65).Results:The lung organ coefficient and W/D value were significantly decreased in the CBD administration group(P<0.05);medium and high doses of CBD could reduce the number of collagen fibers and fibroblasts;the pulmonary fibrosis in the low,medium,and high dose groups of CBD was significantly lower.The levels of TNF-α,IL-1β,and IL-6 in rat serum,as well as MDA and HYP in lung tissue,were significantly lower compared to the model group.Additionally,the level of SOD was significantly increased(P<0.05);The expression ofα-SMA was decreased compared with the model group(P<0.05);the contents of TGF-β1,α-SMA and NF-κB p65 mRNA in lung tissue decreased,and the expression level of Nrf2 mRNA increased(P<0.05).Especially,the high-dose group had the most significant effect.Conclusion:CBD can significantly reduce the degree of pulmonary fibrosis in rats,and its potential mechanism may be related to inhibiting inflammatory response,enhancing antioxidant capacity and inhibiting the protein expression of TGF-β1 andα-SMA.展开更多
<strong>Introduction:</strong> Epilepsy is considered a chronic neurological condition that manifests itself with seizures, where 30% - 40% of patients do not achieve control of their seizures despite prop...<strong>Introduction:</strong> Epilepsy is considered a chronic neurological condition that manifests itself with seizures, where 30% - 40% of patients do not achieve control of their seizures despite proper management. Seizures represent a significant limitation in the patient’s daily activities and are often accompanied by emotional and relational difficulties that have a great impact on the quality of life of the patient and their families. Cannabidiol (CBD) has been found to be effective in controlling seizures and may also improve cognitive and behavioral abilities. <strong>Material and Methods:</strong> The Quality of Life of the Patient with Epilepsy (CAVE) scale was applied to patients with refractory epilepsies who use Cannabidiol (CBD) added to their base therapy, before the use of CBD and after 12 months of follow-up. The presentation of collateral effects was also evaluated. <strong>Results:</strong> Out of 34 patients, 26 (76.5%) increased their CAVE value at the end of the study and only 1 (2.9%) decreased. 19 (55.9%) improved in learning and behavior, 55.8% in the frequency of seizures and 79.4% reported a decrease in the intensity of seizures. There were other positive side effects such as improvement in alertness, language, sleep and behavior. The main side effects were mild and transitory, including drowsiness, and constipation. There was a correlation between the global perception of improvement and seizure control. <strong>Conclusions:</strong> This study shows that in the long term CBD improves the quality of life of patients with refractory epilepsies, through the control of seizures and the improvement of cognitive and behavioral functions.展开更多
Cannabidiol(CBD)is a physiologically active natural substance,usually extracted from the flowers and leaves of hemp.CBD not only has the function of alleviating the symptoms of many mental disorders,but also has the f...Cannabidiol(CBD)is a physiologically active natural substance,usually extracted from the flowers and leaves of hemp.CBD not only has the function of alleviating the symptoms of many mental disorders,but also has the function of anti-inflammation,anti-oxidation and treatment of skin diseases.Because of its beneficial effects,CBD has been used as an important raw material in the production of health care products and skin care products,which have already been sold on the market.This paper reviewed the main preparation techniques of CBD.The author developed a new refining process for CBD purification combining molecular distillation and crystallization.This new process is both environmental friendly and economical.The obtained samples meet the requirements of the cosmetic industry.The paper also introduces the application prospect of CBD products in daily Chemical Industry,especially in skin care.展开更多
Cannabidiol(CBD),a non-psychoactive cannabinoid,shows great promise in treating methamphetamine(METH)addiction.Nonetheless,the molecular target and the mechanism through which CBD treats METH addiction remain unexplor...Cannabidiol(CBD),a non-psychoactive cannabinoid,shows great promise in treating methamphetamine(METH)addiction.Nonetheless,the molecular target and the mechanism through which CBD treats METH addiction remain unexplored.Herein,CBD was shown to counteract METH-induced locomotor sensitization and conditioned place preference.Additionally,CBD mitigated the adverse effects of METH,such as cristae loss,a decline in ATP content,and a reduction in membrane potential.Employing an activity-based protein profiling approach,a target fishing strategy was used to uncover CBD's direct target.ATP5A1,a subunit of ATP synthase,was identified and validated as a CBD target.Moreover,CBD demonstrated the ability to ameliorate METH-induced ubiquitination of ATP5A1 via the D376 residue,thereby reversing the METH-induced reduction of ATP5A1 and promoting the assembly of ATP synthase.Pharmacological inhibition of the ATP efflux channel pannexin 1,blockade of ATP hydrolysis by a CD39 inhibitor,and blocking the adenosine A1 receptor(A1R)all attenuated the therapeutic benefits of CBD in mitigating METH-induced behavioral sensitization and CPP.Moreover,the RNA interference of ATP5A1 in the ventral tegmental area resulted in the reversal of CBD's therapeutic efficacy against METH addiction.Collectively,these data show that ATP5A1 is a target for CBD to inhibit METH-induced addiction behaviors through the ADO-A1R signaling pathway.展开更多
Background Epilepsy is a neurological syndrome caused by excessive neuronal discharges,with a part of the patients being pharmacoresistant to the traditional treatment.Cannabidiol,a non-psychoactive component of Canna...Background Epilepsy is a neurological syndrome caused by excessive neuronal discharges,with a part of the patients being pharmacoresistant to the traditional treatment.Cannabidiol,a non-psychoactive component of Cannabis Sativa,shows promise as an alternative,but further research is needed to quantify its efcacy.Methods This literature systematic review was made following the PRISMA protocol guidelines.The Google Scholar,Scielo,and PubMed/MEDLINE databases were included using the descriptors“Cannabidiol”,“Epilepsy”,and“Drug Resistant Epilepsy”.This research was registered in the Prospero platform with the identifcation(CRD42024479643).Results A total of 1448 results were identifed from the PubMed,Virtual Health Library,and Google Scholar databases.After applying exclusion criteria,six studies met the criteria for full-text evaluation and eligibility.The compiled analysis showed that the patients who received cannabidiol experienced a 41.0875%reduction in the total number of seizures,compared to an average reduction of 18.1%in placebo groups.This represents a 127%higher response rate for patients who received the intervention.Conclusions Given these results,it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential.However,the high efcacy rate observed in the placebo group suggests that other methods of data collection analysismay be employed.展开更多
This study reviews the anti-inflammatory potential of cannabidiol(CBD)in the management of type 1 diabetes(T1D).A comprehensive search was conducted across PubMed,Scopus,and ScienceDirect databases using the terms“ty...This study reviews the anti-inflammatory potential of cannabidiol(CBD)in the management of type 1 diabetes(T1D).A comprehensive search was conducted across PubMed,Scopus,and ScienceDirect databases using the terms“type 1 diabetes”,“cannabidiol”,“anti-inflammatory effect”,and“CBD”.Articles published between 2005 and 2025 were screened,and studies involving animal models that examined CBD as a therapeutic intervention for T1D and reported on its antiinflammatory effects were included.Of the 62 retrieved articles,only 6 met the predefined inclusion criteria.Although limited in number,the available studies show promising outcomes.CBD demonstrates potential as an adjuvant therapy for T1D due to its immunomodulatory and anti-inflammatory actions.Nonetheless,further research is required to establish safe and effective clinical application protocols.展开更多
文摘Bone marrow serves as the life-long home for hemato-poietic stem cells(HSCs)and is the most radio-sensitive organ^([1]).Acute ionizing radiation exceeding 1 Gray(Gy)causes severe damage in bone marrow while no effective drug has been approved in clinical.In a recent work pub-lished in MedComm,Gao and her team reported,for the first time,cannabidiol(CBD)as an outstanding radioprotection agent targeting acute radiation-induced hematopoietic injury^([2]).Within two weeks post radiation,CBD can pro-mote the stemness of hematopoietic stem cells to a regular level.Using single-cell RNA sequencing(scRNA-seq)and functional assay,the authors decoded molecular changes underlying radiation-induced damage and CBD-induced recovery in HSCs.
基金National Research Fund of South Africa(grant number:137792).
文摘Background:Cannabidiol(CBD)has numerous therapeutic properties,and is used to treat neurological conditions,such as neuroinflammation.However,the optimal dose of CBD to penetrate the brain requires further investigation.The primary aim of this study was to use a mouse model and the intrabuccal route for CBD administration to determine the optimal dose at which CBD can penetrate the brain.The secondary aim was to determine whether sex is a confounding factor.Methods:Thirty adult Kramnik mice,divided equally into three groups,were ad-ministered CBD oil intrabuccally at three doses-10,20,and 30 mg/kg,euthanized 6 h later,and whole brain,urine,and blood samples were collected.Liquid chro-matography with tandem mass spectrometry was used to analyze the collected samples.Results:CBD and its three metabolites—7-carboxy cannabidiol(7-COOH-CBD),7-hydroxy cannabidiol(7-OH-CBD)and 6-hydroxy cannabidiol(6-OH-CBD),were identified and quantified in all samples.The 10 and 20 mg/kg doses of CBD produced similar results in the brain,but the group given the 10 mg/kg dose had the least vari-ation.The 30 mg/kg dose yielded the highest abundance of CBD and its metabolites in all samples,but also the greatest variation.Sex only became a confounding factor at 30 mg/kg.Conclusions:This study shows that the intrabuccal route of CBD administration is reliable and the 10 mg/kg dose of CBD is recommended in mice because there were good CBD metabolite concentrations in all samples,with the least variation among the doses,and sex was not a confounder at 10 mg/kg.
基金supported by grants from Jazz Pharmaceuticals Inc.the Texas A&M University of School of Medicine to AKS
文摘Background:Chronic Gulf War Illness(GWI)is characterized by cognitive and mood impairments,as well as persistent neuroinflammation and oxidative stress.This study aimed to investigate the efficacy of Epidiolex®,a Food and Drug Administration(FDA)-approved cannabidiol(CBD),in improving brain function in a rat model of chronic GWI.Methods:Six months after exposure to low doses of GWI-related chemicals[pyridostigmine bromide,N,N-diethyl-meta-toluamide(DEET),and permethrin(PER)]along with moderate stress,rats with chronic GWI were administered either vehicle(VEH)or CBD(20 mg/kg,oral)for 16 weeks.Neurobehavioral tests were conducted on 11 weeks after treatment initiation to evaluate the performance of rats in tasks related to associative recognition memory,object location memory,pattern separation,and sucrose preference.The effect of CBD on hyperalgesia was also examined.The brain tissues were processed for immunohistochemical and molecular studies following behavioral tests.Results:GWI rats treated with VEH exhibited impairments in all cognitive tasks and anhedonia,whereas CBD-treated GWI rats showed improvements in all cognitive tasks and no anhedonia.Additionally,CBD treatment alleviated hyperalgesia in GWI rats.Analysis of hippocampal tissues from VEH-treated rats revealed astrocyte hypertrophy and increased percentages of activated microglia presenting NOD-,LRR-and pyrin domain-containing protein 3(NLRP3)complexes as well as elevated levels of proteins involved in NLRP3 inflammasome activation and Janus kinase/signal transducers and activators of the transcription(JAK/STAT)signaling.Furthermore,there were increased concentrations of proinflammatory and oxidative stress markers along with decreased neurogenesis.In contrast,the hippocampus from CBD-treated GWI rats displayed reduced levels of proteins mediating the activation of NLRP3 inflammasomes and JAK/STAT signaling,normalized concentrations of proinflammatory cytokines and oxidative stress markers,and improved neurogenesis.Notably,CBD treatment did not alter the concentration of endogenous cannabinoid anandamide in the hippocampus.Conclusions:The use of an FDA-approved CBD(Epidiolex®)has been shown to effectively alleviate cognitive and mood impairments as well as hyperalgesia associated with chronic GWI.Importantly,the improvements observed in rats with chronic GWI in this study were attributed to the ability of CBD to significantly suppress signaling pathways that perpetuate chronic neuroinflammation.
基金Supported by Central Government Supports Local College Reform and Development Fund Talent Training Projects(2020GSP16)Heilongjiang Provincial Key Research and Development Plan Guidance Project(GZ20220039).
文摘Cannabidiol(CBD)is the active constituent of Cannabis sativa and exhibits a diverse range of pharmacologic effects,including anticancer,antibacterial,anti-inflammatory,antioxidant,and antiepileptic properties.The pharmacologic effects of CBD and its molecular mechanisms are reviewed with the objective of proposing novel approaches for basic research and clinical applications of CBD and related pharmaceuticals.
文摘Background: Myocardial ischemia in addition to other several cardiac syndromes represent a pathological proinflammatory state alongside a complex cellular microenvironment that can be modified by using cannabinoids. Cannabidiol (CBD), a non-psychoactive compound of cannabis has been recently proposed as an immudomodulatory and cardioprotective drug. Objectives: In this systematic review we sought to clarify and summarize the clinical and preclinical evidence of potential benefit of the use of CBD in coronary syndromes. Methods: We conducted a systematic search and review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Review of Animal Data from Experimental Studies (CAMARADES) guidelines, in the electronic database from PubMed, Web of Science and Scopus up to April 2022 using predefined search terms. Pre-specified exclusion and inclusion criteria were considered, finally 11 articles were chosen to be included for this peer review. Results: Currently there are no good-quality clinical trials with the use of CBD in acute or chronic coronary syndromes. A total of 11 preclinical studies where prescreened and 5 demonstrated reproducible positive cardiovascular outcomes on in-vivo models treated with CBD. Mechanisms of CBD cardioprotection observed: 1) reduction in oxidative stress and inflammation, 2) activation of adenosine receptors and 3) increased expression of angiotensin type 2-receptor. Experimental models included ischemia/reperfusion injury, myocardial infarction, arrhythmias, and metabolic syndrome-like conditions. Conclusion: No clinical recommendation can be issued with the current evidence, on the use of CBD in acute and chronic coronary syndromes. Based on preclinical evidence, we considered there is enough evidence to propose the development of well-designed clinical trials that include CBD in the management of coronary syndromes.
基金supported by the National Key Research and Development Plan,China(Grant No.:2022YFC3500202)the Natural Science Foundation of China(Grant Nos.:82172558,and 82205024)+4 种基金the Scientific and Technological Innovation Action Plan of Natural Science Foundation Project of Shanghai,China(Grant No.:22ZR1447400)the Scientific and Technological Innovation Action Plan,China(Grant No.:22ZR1447400)the Fundamental Research Funds for the Central Universities,China(Grant Nos.:020814380179,020814380174)the Distinguished Young Scholars of Nanjing,China(Grant No.:JQX20008)the School of Life Science(NJU)-Sipimo Joint Funds and Mountain Climbing Talents Project of Nanjing University,China(Grant No.:2015018).
文摘Colorectal tumors often create an immunosuppressive microenvironment that prevents them from responding to immunotherapy.Cannabidiol(CBD)is a non-psychoactive natural active ingredient from the cannabis plant that has various pharmacological effects,including neuroprotective,antiemetic,anti-inflammatory,and antineoplastic activities.This study aimed to elucidate the specific anticancer mechanism of CBD by single-cell RNA sequencing(scRNA-seq)and single-cell ATAC sequencing(scATAC-seq)technologies.Here,we report that CBD inhibits colorectal cancer progression by modulating the suppressive tumor microenvironment(TME).Our single-cell transcriptome and ATAC sequencing results showed that CBD suppressed M2-like macrophages and promoted M1-like macrophages in tumors both in strength and quantity.Furthermore,CBD significantly enhanced the interaction between M1-like macrophages and tumor cells and restored the intrinsic anti-tumor properties of macrophages,thereby preventing tumor progression.Mechanistically,CBD altered the metabolic pattern of macrophages and related anti-tumor signaling pathways.We found that CBD inhibited the alternative activation of macrophages and shifted the metabolic process from oxidative phosphorylation and fatty acid oxidation to glycolysis by inhibiting the phosphatidylinositol 3-kinase-protein kinase B signaling pathway and related downstream target genes.Furthermore,CBD-mediated macrophage plasticity enhanced the response to anti-programmed cell death protein-1(PD-1)immunotherapy in xenografted mice.Taken together,we provide new insights into the anti-tumor effects of CBD.
文摘Cannabinoids, the active components of Cannabis sativa Linnaeus, have received renewed interest in recent years due to their diverse pharmacologic activities such as cell growth inhibition, anti-inflammatory effects and tumor regression, but their use in chemotherapy is limited by their psychotropic activity. To date, cannabinoids have been successfully used in the treatment of nausea and vomiting, two common side effects that accompany chemotherapy in cancer patients. Most non-THC plant cannabinoids e.g. cannabidiol and cannabigerol, seem to be devoid of psychotropic properties. However, the precise pathways through which these molecules produce an antitumor effect have not yet been fully characterized. We therefore investigated the antitumor and anti-inflammatory activities of cannabidiol (CBD) in human prostate cancer cell lines LNCaP, DU145, PC3, and assessed whether there is any advantage in using cannabis extracts enriched in cannabidiol and low in THC. Results obtained in a panel of prostate cancer cell lines clearly indicate that cannabidiol is a potent inhibitor of cancer cell growth, with significantly lower potency in non-cancer cells. The mRNA expression level of cannabinoid receptors CB1 and CB2, vascular endothelial growth factor (VEGF), PSA (prostate specific antigen) are significantly higher in human prostate cell lines. Treatment with Cannabis extract containing high CBD down regulates CB1, CB2, VEGF, PSA, pro-inflammatory cytokines/chemokine IL-6/IL-8. Our overall findings support the concept that cannabidiol, which lacks psychotropic activity, may possess anti-inflammatory property and down regulates both cannabinoid receptors, PSA, VEGF, IL-6 and IL-8. High CBD cannabis extracts are cytotoxic to androgen responsive LNCaP cells and may effectively inhibit spheroid formation in cancer stem cells. This activity may contribute to its anticancer and chemosensitizing effect against prostate cancer. Cannabidiol and other non-habit forming cannabinoids could be used as novel therapeutic agents for the treatment of prostate cancer.
文摘Cannabidiol(CBD),a nonpsychotropic phytocannabinoid that was once largely disregarded,is currently the subject of significant medicinal study.CBD is found in Cannabis sativa,and has a myriad of neuropharmacological impacts on the central nervous system,including the capacity to reduce neuroinflammation,protein misfolding and oxidative stress.On the other hand,it is well established that CBD generates its biological effects without exerting a large amount of intrinsic activity upon cannabinoid receptors.Because of this,CBD does not produce undesirable psychotropic effects that are typical of marijuana derivatives.Nonetheless,CBD displays the exceptional potential to become a supplementary medicine in various neurological diseases.Curently,many clinical trials are being conducted to investigate this possibility.This review focuses on the therapeutic effects of CBD in managing neurological disorders like Alzheimer's disease,Parkinson's disease and epilepsy.Overall,this review aims to build a stronger understanding of CBD and provide guidance for future fundamental scientific and clinical investigations,opening a new therapeutic window for neuroprotection.
文摘Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti-inflammatory and anti-anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell-shaped dose-response was observed, which limits its clinical use. In the present study, we have studied in mice the anti-inflammatory and anti-nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan-induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD. We therefore propose that Cannabis clone 202 (Avidekel) extract is superior over CBD for the treatment of inflammatory conditions.
基金The authors sincerely acknowledge the funding(Sanction Order No.DST/Inspire Fellowship/2016/IF160620)dated 01-22-2020 and support provided by the Department of Science and Technology,Govt.of India and University Grants Commission,New Delhi.
文摘Δ9-tetrahydrocannabinol(THC)of cannabis is the main psychoactive component which is a global significant concern to human health.Evaluation on THC reported its drastic effect on the brain dopaminergic(DAergic)system stimulating mesolimbic DA containing neurons thereby increasing the level of striatal DA.Cannabidiol(CBD),with its anxiolytic and anti-psychotic property,is potent to ameliorate the THC-induced DAergic variations.Legal authorization of cannabis use and its analogs in most countries led to a drastic dispute in the elicitation of cannabis products.With a recent increase in cannabis-induced disorder rates,the present review highlighted the detrimental effects of THC and the effects of CBD on THC induced alterations in DA synthesis and release.Alongside the reported data,uses of cannabis as a therapeutic medium in a number of health complications are also being briefly reviewed.These evaluated reports led to an anticipation of additional research contradictory to the findings of THC and CBD activity in the brain DAergic system and their medical implementations as therapeutics.
文摘Background and purpose: Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has been shown by us, to have an anti-inflammatory effect in collagen-induced arthritis in DBA mice and in type 1 diabetes in NOD mice. As inflammation is a process involved in diabetes type 2, we administered CBD to Psammomys obesus (sand rats), a species which develops diabetes type 2 when fed high-energy (HE) diet, to investigate whether we can hinder the development of the disease. Experimental Approach: Male Psammomys obesus were kept on a high energy diet during the experiments. They were treated with CBD (i.p injection, 5 mg/kg, 5 times/week) for 4 weeks and kept (without CBD) for another 29 - 39 days. The weights of the animals as well as blood glucose and plasma insulin levels were determined and the morphology of the pancreatic islets was examined. Key results: CBD significantly reduced blood glucose levels in Psammomys obesus, without effecting body weight. Plasma insulin levels were significantly higher in the CBD-treated group. The most striking effect noted was the marked decrease of the destruction of pancreatic islets and beta cells. Conclusions and implications: CBD partially protects pancreatic islets and beta cells from destruction. CBD lowers significantly the blood glucose level and increases insulin level in Psammomys obesus with diabetes type 2, but does not lead to obesity. As CBD already has been administered to patients for other medical indications we propose its use as a therapeutic agent in diabetes type 2.
文摘Cannabidiol (CBD), one of the most studied phytocannabinoids, is non-psychotropic and can induce protective effects on the central nervous system against acute and chronic brain injury. Interestingly, CBD inhibits processes relating to amyloid beta (Aβ)-induced neurotoxicity in mouse models of Alzheimer’s disease, though the detailed molecular mechanism underlying the CBD neurotoxicity modulation is not fully understood. In this study, using atomic force microscopy, we find that CBD promotes the aggregation of Aβ peptides, enhancing the formation of Aβ oligomers, also known as Aβ-derived diffusible ligands (ADDLs). The CBD-mediated sequestration of Aβ monomers in soluble ADDLs could reduce neurotoxicity. This study highlights a possible role of CBD in modulating the formation of ADDL aggregates and provides insight into potentially neuroprotective properties of CBD in Alzheimer’s disease.
基金Post-doctoral Program of Heilongjiang Province (No.LBH-Z22251)Chinese Medicine Research Project of Heilongjiang Province (No.ZHY2022-114)Heilongjiang Chinese Medicine Association Youth Talent Promotion Project (No.2022-QNRC1-27)。
文摘Objective:To study the protective effect of cannabidiol(CBD)on rats with pulmonary fibrosis and explore the possible mechanism of the use of CBD in the treatment of pulmonary fibrosis.Methods:Sixty SD rats were randomly divided into the normal control group,model group,prednisone group,CBD low,medium and high dose groups(12,36,108 mg/kg,ig),10 rats in each group.Except for the normal control group,the other 5 groups were all induced by tracheal injection of bleomycin to rat models of pulmonary fibrosis.After modeling,the rats were given intragastric administration once a day for 28 consecutive days and samples were taken.The degree of pulmonary edema was detected;the pathological changes of lung tissue were observed by HE and Masson staining;tumor necrosis factorα(TNF-α),interleukin-1β(IL-1β),interleukin-6(IL-6)and lung tissue superoxide dismutase(SOD),malondialdehyde(MDA),hydroxyproline(HYP)contents were measured by ELISA,transforming growth factor-β1(TGF-β1)andα-smooth muscle protein(α-SMA)concentration were detected by immunocytochemical method,real-time fluorescent quantitative PCR(qRT-PCR)method was used to detect the mRNA expression levels of TGF-β1,α-SMA,Nrf2 and nuclear transcription factor-κB p65(NF-κB p65).Results:The lung organ coefficient and W/D value were significantly decreased in the CBD administration group(P<0.05);medium and high doses of CBD could reduce the number of collagen fibers and fibroblasts;the pulmonary fibrosis in the low,medium,and high dose groups of CBD was significantly lower.The levels of TNF-α,IL-1β,and IL-6 in rat serum,as well as MDA and HYP in lung tissue,were significantly lower compared to the model group.Additionally,the level of SOD was significantly increased(P<0.05);The expression ofα-SMA was decreased compared with the model group(P<0.05);the contents of TGF-β1,α-SMA and NF-κB p65 mRNA in lung tissue decreased,and the expression level of Nrf2 mRNA increased(P<0.05).Especially,the high-dose group had the most significant effect.Conclusion:CBD can significantly reduce the degree of pulmonary fibrosis in rats,and its potential mechanism may be related to inhibiting inflammatory response,enhancing antioxidant capacity and inhibiting the protein expression of TGF-β1 andα-SMA.
文摘<strong>Introduction:</strong> Epilepsy is considered a chronic neurological condition that manifests itself with seizures, where 30% - 40% of patients do not achieve control of their seizures despite proper management. Seizures represent a significant limitation in the patient’s daily activities and are often accompanied by emotional and relational difficulties that have a great impact on the quality of life of the patient and their families. Cannabidiol (CBD) has been found to be effective in controlling seizures and may also improve cognitive and behavioral abilities. <strong>Material and Methods:</strong> The Quality of Life of the Patient with Epilepsy (CAVE) scale was applied to patients with refractory epilepsies who use Cannabidiol (CBD) added to their base therapy, before the use of CBD and after 12 months of follow-up. The presentation of collateral effects was also evaluated. <strong>Results:</strong> Out of 34 patients, 26 (76.5%) increased their CAVE value at the end of the study and only 1 (2.9%) decreased. 19 (55.9%) improved in learning and behavior, 55.8% in the frequency of seizures and 79.4% reported a decrease in the intensity of seizures. There were other positive side effects such as improvement in alertness, language, sleep and behavior. The main side effects were mild and transitory, including drowsiness, and constipation. There was a correlation between the global perception of improvement and seizure control. <strong>Conclusions:</strong> This study shows that in the long term CBD improves the quality of life of patients with refractory epilepsies, through the control of seizures and the improvement of cognitive and behavioral functions.
文摘Cannabidiol(CBD)is a physiologically active natural substance,usually extracted from the flowers and leaves of hemp.CBD not only has the function of alleviating the symptoms of many mental disorders,but also has the function of anti-inflammation,anti-oxidation and treatment of skin diseases.Because of its beneficial effects,CBD has been used as an important raw material in the production of health care products and skin care products,which have already been sold on the market.This paper reviewed the main preparation techniques of CBD.The author developed a new refining process for CBD purification combining molecular distillation and crystallization.This new process is both environmental friendly and economical.The obtained samples meet the requirements of the cosmetic industry.The paper also introduces the application prospect of CBD products in daily Chemical Industry,especially in skin care.
基金supported by the National Natural Science Foundation of China(22207105,22277118,T2241028)the STI2030-Major Projects(2021ZD0203000(2021ZD0203003),China)+6 种基金Talent Introduction Project of Shandong First Medical University funds under Grant YS23-0000349the Science and Technology Innovation Program of the Chinese Academy of Agricultural Sciences(No.CAAS-ASTIP-2021-ISAPS,China)the Key Science and Technology Project of Jilin Province(20200504001YY,China)Science and Technology Development Plan Project of Jilin Province(20220204045GH,China)International Partnership Program of the Chinese Academy of Sciences(029GJHZ2024057GC,China)Open Research Fund of the State Key Laboratory of Brain Machine Intelligence,Zhejiang University(BMI2400014,China)National Natural Science Foundation of Hunan Province(2025JJ70246,China).
文摘Cannabidiol(CBD),a non-psychoactive cannabinoid,shows great promise in treating methamphetamine(METH)addiction.Nonetheless,the molecular target and the mechanism through which CBD treats METH addiction remain unexplored.Herein,CBD was shown to counteract METH-induced locomotor sensitization and conditioned place preference.Additionally,CBD mitigated the adverse effects of METH,such as cristae loss,a decline in ATP content,and a reduction in membrane potential.Employing an activity-based protein profiling approach,a target fishing strategy was used to uncover CBD's direct target.ATP5A1,a subunit of ATP synthase,was identified and validated as a CBD target.Moreover,CBD demonstrated the ability to ameliorate METH-induced ubiquitination of ATP5A1 via the D376 residue,thereby reversing the METH-induced reduction of ATP5A1 and promoting the assembly of ATP synthase.Pharmacological inhibition of the ATP efflux channel pannexin 1,blockade of ATP hydrolysis by a CD39 inhibitor,and blocking the adenosine A1 receptor(A1R)all attenuated the therapeutic benefits of CBD in mitigating METH-induced behavioral sensitization and CPP.Moreover,the RNA interference of ATP5A1 in the ventral tegmental area resulted in the reversal of CBD's therapeutic efficacy against METH addiction.Collectively,these data show that ATP5A1 is a target for CBD to inhibit METH-induced addiction behaviors through the ADO-A1R signaling pathway.
文摘Background Epilepsy is a neurological syndrome caused by excessive neuronal discharges,with a part of the patients being pharmacoresistant to the traditional treatment.Cannabidiol,a non-psychoactive component of Cannabis Sativa,shows promise as an alternative,but further research is needed to quantify its efcacy.Methods This literature systematic review was made following the PRISMA protocol guidelines.The Google Scholar,Scielo,and PubMed/MEDLINE databases were included using the descriptors“Cannabidiol”,“Epilepsy”,and“Drug Resistant Epilepsy”.This research was registered in the Prospero platform with the identifcation(CRD42024479643).Results A total of 1448 results were identifed from the PubMed,Virtual Health Library,and Google Scholar databases.After applying exclusion criteria,six studies met the criteria for full-text evaluation and eligibility.The compiled analysis showed that the patients who received cannabidiol experienced a 41.0875%reduction in the total number of seizures,compared to an average reduction of 18.1%in placebo groups.This represents a 127%higher response rate for patients who received the intervention.Conclusions Given these results,it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential.However,the high efcacy rate observed in the placebo group suggests that other methods of data collection analysismay be employed.
文摘This study reviews the anti-inflammatory potential of cannabidiol(CBD)in the management of type 1 diabetes(T1D).A comprehensive search was conducted across PubMed,Scopus,and ScienceDirect databases using the terms“type 1 diabetes”,“cannabidiol”,“anti-inflammatory effect”,and“CBD”.Articles published between 2005 and 2025 were screened,and studies involving animal models that examined CBD as a therapeutic intervention for T1D and reported on its antiinflammatory effects were included.Of the 62 retrieved articles,only 6 met the predefined inclusion criteria.Although limited in number,the available studies show promising outcomes.CBD demonstrates potential as an adjuvant therapy for T1D due to its immunomodulatory and anti-inflammatory actions.Nonetheless,further research is required to establish safe and effective clinical application protocols.
